^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BM-ca
i
Other names: BM-ca
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Institute of Immunology
Drug class:
CD20 inhibitor
Related drugs:
2years
A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=9, Not yet recruiting, Zhejiang University
New P1 trial • CAR T-Cell Therapy
|
GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
|
BM-ca • OriC321
Share via
